Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MCL1 | Q07820 | 6/20 | 0.51 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.48 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.48 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.47 |
| ▸ | MEN1 | O00255 | 3/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.47 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.47 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.47 |
| ▸ | LMNA | P02545 | 2/20 | 0.47 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.47 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.47 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.47 |
| ▸ | HTT | P42858 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.46 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4022584 | 0.80 | CES2 (0.46) | MCL1L3MBTL1ALDH1A1MEN1KMT2A | |
| SCHEMBL1758554 | 0.80 | MEN1 (0.48) | MCL1CHRNA7TRPV1MEN1KMT2A | |
| SCHEMBL1133023 | 0.76 | MCL1 (0.51) | MCL1CHRNA7TRPV1ALDH1A1MEN1 | |
| SCHEMBL11055193 | 0.76 | MCL1 (0.54) | MCL1CHRNA7TRPV1ALDH1A1MEN1 | |
| SCHEMBL883518 | 0.76 | MCL1 (0.51) | MCL1CHRNA7TRPV1ALDH1A1CYP1A2 | |
| SCHEMBL17671209 | 0.76 | HDAC1 (0.54) | MCL1CHRNA7TRPV1ALDH1A1MEN1 | |
| SCHEMBL20472469 | 0.75 | CHRNA7 (0.76) | L3MBTL1CHRNA7TRPV1ALDH1A1MEN1 | |
| SCHEMBL29776952 | 0.75 | CHRNA7 (0.76) | L3MBTL1CHRNA7TRPV1ALDH1A1MEN1 | |
| SCHEMBL1758609 | 0.75 | ALDH1A1 (0.54) | MCL1CHRNA7TRPV1ALDH1A1MEN1 | |
| SCHEMBL1758628 | 0.75 | MEN1 (0.50) | MCL1ALDH1A1MEN1KMT2AHDAC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6362342-B1 | BIOSYNTHESIS; DRUG LIBRARIES | LION BIOSCIENCE AG (DE) | 2002-03-26 | — | — | US | claimed |
| EP-2493886-B1 | HETEROARYL PIPERIDINE AND PIPERAZINE DERIVATES | BAYER CROPSCIENCE AG (DE) | 2014-11-26 | — | — | EP | disclosed |
| US-8501781-B2 | Heteroarylpiperidine and -piperazine derivatives | BAYER CROPSCIENCE AG (DE) | 2013-08-06 | — | — | US | disclosed |
| EP-2493886-A1 | HETEROARYLPIPERIDINE AND -PIPERAZINE DERIVATIVES | Bayer CropScience AG (DE) | 2012-09-05 | — | — | EP | disclosed |
| US-20110306620-A1 | Heteroarylpiperidine And-Piperazine Derivatives | BAYER CROPSCIENCE AG (DE) | 2011-12-15 | — | — | US | disclosed |
| WO-2011051244-A1 | HETEROARYLPIPERIDINE AND -PIPERAZINE DERIVATIVES | BAYER CROPSCIENCE AG (DE) | 2011-05-05 | — | — | WO | disclosed |
| US-20070276011-A1 | Plasminogen Activator Inhibitor-1 Inhibitor | INSTITUTE OF MEDICINAL MOLECULAR DESIGN. INC. (JP) | 2007-11-29 | — | — | US | disclosed |
| EP-1666469-A1 | PLASMINOGEN ACTIVATOR INHIBITOR-1 INHIBITOR | Institute of Medicinal Molecular Design, Inc. (JP) | 2006-06-07 | — | — | EP | disclosed |
| EP-1189891-A1 | TRIAZOLE COMPOUNDS AND COMBINATORIAL LIBRARIES THEREOF | LION Bioscience AG (DE) | 2002-03-27 | — | — | EP | disclosed |
| US-6362342-B1 | BIOSYNTHESIS; DRUG LIBRARIES | LION BIOSCIENCE AG (DE) | 2002-03-26 | — | — | US | disclosed |
| WO-2001000594-A1 | TRIAZOLE COMPOUNDS AND COMBINATORIAL LIBRARIES THEREOF | LION BIOSCIENCE AG (DE) | 2001-01-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110306620-A1 | Heteroarylpiperidine And-Piperazine Derivatives | CAT, DPM1, ERG28 | MCL1 1916/4885L3MBTL1 3492/4885CHRNA7 3766/4885 |
| US-20070276011-A1 | Plasminogen Activator Inhibitor-1 Inhibitor | SERPINE1, SERPINC1, SERPINB1 | MCL1 3809/4885L3MBTL1 1479/4885CHRNA7 4785/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.